Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. Hornak T, et al. Among authors: jarosova m. Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317312
Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.
Pavlik T, Janousova E, Mayer J, Indrak K, Jarosova M, Klamova H, Zackova D, Voglova J, Faber E, Karas M, Machova Polakova K, Racil Z, Demeckova E, Demitrovicova L, Tothova E, Chudej J, Markuljak I, Cmunt E, Kozak T, Muzik J, Dusek L. Pavlik T, et al. Among authors: jarosova m. Am J Hematol. 2013 Sep;88(9):790-7. doi: 10.1002/ajh.23508. Epub 2013 Jul 23. Am J Hematol. 2013. PMID: 23760739 Free article.
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response.
Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rozmanová S, Jarosová M, Indrák K, Adam T. Faber E, et al. Among authors: jarosova m. Int J Hematol. 2010 Jun;91(5):897-902. doi: 10.1007/s12185-010-0576-y. Epub 2010 May 1. Int J Hematol. 2010. PMID: 20437122
Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry.
Faber E, Mužík J, Koza V, Demečková E, Voglová J, Demitrovičová L, Chudej J, Markuljak I, Cmunt E, Kozák T, Tóthová E, Jarošová M, Dušek L, Indrák K. Faber E, et al. Among authors: jarosova m. Eur J Haematol. 2011 Aug;87(2):157-68. doi: 10.1111/j.1600-0609.2011.01637.x. Eur J Haematol. 2011. PMID: 21535160
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P, Faber E, Divoka M, Rozmanova S, Friedecky D, Jarosova M, Indrak K. Rohon P, et al. Among authors: jarosova m. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013. PMID: 22660209 Free article.
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K. Klamová H, et al. Among authors: jarosova m. Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21. Cancer Med. 2013. PMID: 23634289 Free PMC article.
A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment.
Faber E, Divoká M, Skoumalová I, Novák M, Marešová I, Mičová K, Friedecký D, Adam T, Jarošová M, Indrák K. Faber E, et al. Among authors: jarosova m. Leuk Lymphoma. 2016 Feb;57(2):370-375. doi: 10.3109/10428194.2015.1056184. Epub 2015 Jun 22. Leuk Lymphoma. 2016. PMID: 26022524
Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V, Papajík T, Faber E, Raida L, Kapitáňová Z, Langová K, Prouzová Z, Jarošová M, Indrák K. Procházka V, et al. Among authors: jarosova m. Leuk Lymphoma. 2014 Jul;55(7):1584-90. doi: 10.3109/10428194.2013.850167. Epub 2014 Feb 4. Leuk Lymphoma. 2014. PMID: 24180329
159 results